Citius Oncology (CTOR) EBIT Margin (2025 - 2026)
Citius Oncology (CTOR) recorded quarterly EBIT Margin of 1716.17% in Q1 2026, down 1188.73% quarter-over-quarter from 133.17% in Q4 2025.
Citius Oncology (CTOR) EBIT Margin (2025 - 2026) Analysis & Trends
Citius Oncology's EBIT Margin history runs 2 years deep, the most recent figure standing at 1716.17% for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 20.77% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 23.74% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -122.23% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 21.55% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -12.88% |
| 10 | Citius Oncology | 75.12 Mn | 72.49 Mn | 1.34 Mn | -1,716.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,716.17% |
| Dec 31, 2025 | -133.17% |